Aktuelle Traumatol 2002; 32(3): 143-146
DOI: 10.1055/s-2002-32328
Kasuistik
© Georg Thieme Verlag Stuttgart · New York

Malignes Fibröses Histiozytom im Bereich einer Totalendoprothese des Hüftgelenkes - Koinzidenz oder Komplikation?

Malignant Fibrous Histiocytoma at the Site of THR - Coinicidence or Complication?A.  Schuh 1 , U.  Holzwarth 2 , G.  Zeiler 1
  • 1Orthopädische Klinik Rummelsberg, Schwarzenbruck (Direktor: Prof. Dr. med. G. Zeiler)
  • 2Fa. Peter Brehm, Weißendorf, Germany
Further Information

Publication History

Publication Date:
13 August 2002 (online)

Zusammenfassung

Das Maligne Fibröse Histiozytom (MFH) ist das häufigste Sarkom des Erwachsenenalters. Prädisponierende Faktoren für das MFH stellen der Morbus Paget, Knocheninfarkte, maligne Erkrankungen des hämatopoetischen Systems oder Kortisoneinnahme dar. In letzter Zeit wird das MFH immer öfter in Verbindung mit orthopädischen Implantaten beschrieben und diesen bzw. deren Legierungen zugeschrieben. Das MFH im Bereich der Totalendoprothese des Hüftgelenkes stellt jedoch eine ausgesprochene Rarität dar. Unseres Wissens nach sind in der Weltliteratur bisher 13 Fälle beschrieben. Die in der Literatur beschriebene Therapie reicht von der lokalen Tumorexstirpation bis zur Hemipelvektomie. Wir stellen den Fall einer 66-jährigen Rheumatikerin vor, bei der im Rahmen einer Wechseloperation einer gelockerten Titan-Hüfttotalendoprothese der histopathologische Befund des Granulomgewebes ein MFH III° vom storiform-pleomorphen Typ ergab. Die Standzeit der Primärprothese betrug 8 Jahre. Die Patientin verstarb ein Jahr nach Hemipelvektomie. Bei Lockerungen von (Hüft-)Totalendoprothesen muss auch an maligne Tumoren gedacht werden, wir empfehlen die histopathologische Untersuchung des Granulomgewebes. Es wird ein Literaturüberblick gegeben, die verschiedenen Therapieoptionen aufgezeigt und die mögliche Ursache der Entwicklung von MFH im Zusammenhang mit Endoprothesen diskutiert.

Abstract

The Malignant Fibrous Histiocytoma (MFH) is the most frequent sarcoma in adulthood. Predisposing factors for MFH are Paget's disease, bone infarcts, malignant disorders of the haematopoetic system or the ingestion of corticosteroids. In recent times, MFH is described with increasing frequency in connection with orthopaedic implants, being attributed thereto or to their alloying constituents. MFH at the site of the total endoprosthesis of the hip joint does, however, constitute a distinct rarity. As far as we know, 13 cases have, to date, been described in world literature. The therapy described in the literature ranges from a local tumour extirpation to a hemipelvectomy. We present the case of a 66-year-old female patient suffering from rheumatism, in respect of whom the histopathological findings of the granuloma tissue, undertaken within the framework of an operation to exchange a loosened total titanium hip endoprosthesis, showed a 3rd degree MFH of the storiform-pleomorphic type. The life of the primary prosthesis was 8 years. The patient died a year after revision arthroplasty. In cases where there is a loosening of total (hip) endoprostheses, consideration must also be given to malignant tumours, and we recommend the histopathological examination of the granuloma tissue. An overview of the literature is given, various treatment options are shown, and the possible causes for the development of MFH, in conjunction with endoprostheses, are discussed.

Literatur

  • 1 Aboulafia A J, Littelton K, Shmookler B, Malawer M M. Malignant fibrous histiocytoma at the site of hip replacement in association with chronic infection.  Orthop Rev. 1994;  23 427-432
  • 2 Bago-Granell J, Aguirre-Canyadell M, Nardi J, Tallada N. Malignant fibrous histiocytoma of bone at the site of a total hip arthroplasty. A case report.  J Bone Joint Surg Br. 1984;  66 38-40
  • 3 Bell R S, Hopyan S, Davis A M, Kandel R, Gross A E. Sarcoma of bone-cement membrane: a case report and review of the literature.  Can J Surg. 1997;  40 51-55
  • 4 Boland P J, Huvos A G. Malignant fibrous histiocytoma of bone.  Clin Orthop. 1986;  204 130-134
  • 5 Capanna R, Bertoni F, Bacchini P, Bacci G, Guerra A, Campanacci M. Malignant fibrous histiocytoma of bone. The experience at the Rizzoli Institute: report of 90 cases.  Cancer. 1984;  54 177-187
  • 6 Carter R L, Roe F J. Induction of sarcomas in rats by solid and fragmented polyethylene: experimental observations and clinical implications.  Br J Cancer. 1969;  23 401-407
  • 7 Cole B J, Schultz E, Smilari T F, Hajdu S I, Krauss E S. Malignant fibrous histiocytoma at the site of a total hip replacement: review of the literature and case report.  Skeletal Radiol. 1997;  26 559-563
  • 8 Dahlin D C, Unni K K, Matsuno T. Malignant (fibrous) histiocytoma of bone-fact or fancy?.  Cancer. 1977;  39 1508-1516
  • 9 Dunham W K, Wilborn W H. Malignant fibrous histiocytoma of bone. Report of two cases and review of the literature.  J Bone Joint Surg Am. 1979;  61 939-942
  • 10 Enzinger F M. Malignant fibrous histiocytoma 20 years after Stout.  Am J Surg Pathol. 1986;  10 43-53
  • 11 Galli S J, Weintraub H P, Proppe K H. Malignant fibrous histiocytoma and pleomorphic sarcoma in association with medullary bone infarcts.  Cancer. 1978;  41 607-619
  • 12 Haag M, Adler C P. Malignant fibrous histiocytoma in association with hip replacement.  J Bone Joint Surg Br. 1989;  71 701
  • 13 Hamblen D L, Carter R L. Sarcoma and joint replacement.  J Bone Joint Surg Br. 1984;  66 625-627
  • 14 Jacobs J J, Rosenbaum D H, Hay R M, Gitelis S, Black J. Early sarcomatous degeneration near a cementless hip replacement. A case report and review.  J Bone Joint Surg Br. 1992;  74 740-744
  • 15 Laskin D, Robinson I B, Weinmann J P. Experimental production of sarcomas by methyl methacrylate implants.  Proc Soc Exp Biol Med. 1954;  87 329-345
  • 16 Michael R H, Dorfman H D. Malignant fibrous histiocytoma associated with bone infarcts: report of a case.  Clin Orthop. 1976;  118 180-183
  • 17 Mirra J M, Bullough P G, Marcove R C, Jacobs B, Huvos A G. Malignant fibrous histiocytoma and osteosarcoma in association with bone infarcts; report of four cases, two in caisson workers.  J Bone Joint Surg Am. 1974;  56 932-940
  • 18 Mishra N, Yahiro M, Morrey B F. The Food and Drug Administration's regulation of orthopaedic devices.  J Bone Joint Surg Am. 1994;  76 919-922
  • 19 Nelson J P, Phillips P H. Malignant fibrous histiocytoma associated with total hip replacement. A case report.  Orthop Rev. 1990;  19 1078-1080
  • 20 Solomon M I, Sekel R. Total hip arthroplasty complicated by a malignant fibrous histiocytoma. A case report.  Arthroplasty. 1992;  7 549-550
  • 21 Swanson S A, Freeman M A, Heath J C. Laboratory tests on total joint replacement prostheses.  J Bone Joint Surg Br. 1973;  55 759-773
  • 22 Tait N P, Hacking P M, Malcolm A J. Malignant fibrous histiocytoma occurring at the site of a previous total hip replacement.  Br J Radiol. 1988;  61 73-76
  • 23 Theegarten D, Sardisong F, Philippou S. Malignant fibrous histiocytoma in the area of a total edoprosthesis of the hip joint.  Chirurg. 1995;  66 158-161
  • 24 Troop J K, Mallory T H, Fisher D A, Vaughn B K. Malignant fibrous histiocytoma after total hip arthroplasty. A case report.  Clin Orthop. 1990;  253 297-300
  • 25 Vives P, Sevestre H, Grodet H, Marie F. Malignant fibrous histiocytoma of the femur after total hip prosthesis. Apropos of a case.  Rev Chir Orthop Reparatrice Appar Mot. 1987;  73 407-409
  • 26 Weiss S W, Enzinger F M. Malignant fibrous histiocytoma: an analysis of 200 cases.  Cancer. 1978;  41 2250-2266

Dr. med. Alexander Schuh

Orthopädische Klinik Rummelsberg

Rummelsberg 71 · 90592 Schwarzenbruck

Phone: 0049/9128/50-3333

Email: schuh-alexander@t-online.de